MS and Demyelinating Disorders

The associate professor of neurology at Harvard Medical School talked about the subgroup analysis on ravulizumab in NMOSD that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Gabriel Pardo, MD, FAAN, describes the process that generic RRMS medications have to go through to be approved by the FDA, highlighting the abbreviated new drug application [ANDA] process.

Expert neurologists review availability of generic disease-modifying therapies [DMTs] and the effectiveness of reduced cost to the patient with RRMS

A group of experts in the care of patients with neurological conditions—Ali Jannati, MD, PhD; Madhav R. Thambisetty, MD, PhD; Daniel Ontaneda, MD, PhD; Peter J. Goadsby, MD, PhD, DSc; Andrew Russman, DO—shared their perspectives on hot topics of treatment and management in neurology from the 2023 American Academy of Neurology Annual Meeting.

Higher adherence to Mediterranean Diet Adherence Screener independently predicted 20% lower risk for cognitive impairment among patients with MS.

Dr Mary Ann Picone shares her experience with telehealth care and provides resources for patients and physicians to manage multiple sclerosis treatment in the post-COVID era.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 28, 2023.

Kimberly O’Neill, MD, pediatric neuroimmunology fellow at NYU Langone, discussed her presentation at the 2023 AAN Annual Meeting focused on cognitive similarities between pediatric and adult MS.

The director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute shared his insight into the findings of the World Brain Study, 15 months after its initiation.

Inhibition of serum free complement 5 with ravulizumab was sustained throughout the treatment period according to a pharmacokinetics and pharmacodynamics analysis.

The treatment was superior in preventing on-trial relapse in both the monotherapy and immunosuppressive therapy groups compared with placebo in the CHAMPION-NMOSD trial.

Giants of Multiple Sclerosis is a premier neuroscience award that celebrates pioneers, innovators, and difference makers who have been selected by their peers for their remarkable achievements in multiple sclerosis.

In single-ascending dose and multiple-ascending dose studies, no clinically meaningful changes were noted in hematology, chemistry, vital signs, or electrocardiogram parameters.

After 192 weeks, more than 90% of patients on ocrelizumab had no relapses and slightly more than 80% had no 24-week confirmed disability progression.

Higher rates of no evidence of disease activity and no 24-week confirmed disability progression or relapses were observed in patients that continued with ocrelizumab.

The pediatric neuroimmunology fellow at NYU Langone provided perspective on a study presented at AAN 2023 comparing cognitive trajectories of pediatric and adult multiple sclerosis. [WATCH TIME: 3 minutes]

The panel discusses the value of shared experiences among individuals living with multiple sclerosis.

Craig Mainor and Gina Murdoch share peer-to-peer support resources for individuals living with multiple sclerosis.

Stephen Krieger, MD, discusses how cognition is defined in multiple sclerosis and the tools to evaluate patients' cognitive performance.

The data, from the phase 3 ASCLEPIOS I and II trials and ALITHIOS open-label extension, suggest that most patients remained free from disease progression, with most progression being independent of relapse activity.

Here's some of what is coming soon to NeurologyLive® this week.

An interim analysis showed no reduction in T-cell counts and their subsets as a consequence of B-cell depletion in the first year of treatment with ocrelizumab.

Updated results to the phase 3 CHAMPION-NMOSD trial of ravulizumab showed significantly lower HAI score worsening following treatment.